Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab.

Dystrophic epidermolysis bullosa pruriginosa (DEB-Pr) is a rare subtype of dystrophic epidermolysis bullosa, and traditional treatments have limited efficacy. Dupilumab has demonstrated remarkable efficacy in relieving pruritus. In this case study, after traditional treatment failed, providers recommended the patient begin dupilumab to treat his pruritus.

Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study.

Dupilumab is the first human monoclonal antibody that treats atopic dermatitis (AD) by blocking interleukin 4 (IL-4) and interleukin 13 (IL-13), which can suppress the Th2 inflammatory reaction. Effective treatments for pediatric AD patients are limited; therefore, we aimed to assess the efficacy and safety of dupilumab in pediatric AD patients. Fifteen pediatric patients diagnosed with moderate to severe AD and treated with dupilumab were enrolled in this study.

[MGE-PCR in analyzing the genetic characteristics and the clinical manifestation of Trichomonas vaginalis isolates].

Objective: To analyze the genetic characteristics of Trichomonas vaginalis isolates causing different clinical manifestation.

Method: Mobile genetic factor (MGE)-PCR technique was used for genome amplification in 30 isolates of Trichomonas vaginalis with different clinical manifestation (mild 3, moderate 22, severe 5), and neighbor joining method (NJ) was applied for cluster analysis of the amplified products.

Results: Significant genetic differences were revealed among the isolates, with a distance ranging from 0 to 1 and an average genetic distance of 0.